The best candidates for Semaglutide treatment are individuals struggling with obesity or those who have type 2 diabetes and are looking for effective weight management solutions
At 48 weeks, the least-squares mean percentage change in the retatrutide groups was 8.7% in the 1-mg group, 17.1% in the combined 4-mg group, 22.8% in the combined 8-mg group, and 24.2% in the 12-mg group, as compared with 2.1% in the placebo group
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
First, peptides have proven clinical utility across multiple therapeutic areas, with particular success in endocrine, oncological, and rare disease applications